Media Articles Related to Valturna (Aliskiren / Valsartan)
Two new studies on the connection between hypertension and cognitive decline
Source: Hypertension News From Medical News Today [2015.07.03]
With the number of individuals affected by cognitive decline expected to rise over the next few decades, investigating its potential causes is of major public health interest.
Low levels of hormone in African-Americans may increase hypertension
Source: Endocrinology News From Medical News Today [2015.06.11]
Although hypertension is more common in African-Americans, they have significantly lower levels of a hormone produced in response to cardiac stress than white and Hispanic individuals, a finding that...
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2015.05.29]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 5/29/2015 12:00:00 AM
Source: MedicineNet sildenafil Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM
Picture of Hypertension
Source: MedicineNet Renal Artery Stenosis Specialty [2014.12.09]
Title: Picture of Hypertension
Created: 2/3/2011 12:00:00 AM
Last Editorial Review: 12/9/2014 12:00:00 AM
Published Studies Related to Valturna (Aliskiren / Valsartan)
Comparison of the effects of aliskiren/valsartan in combination versus valsartan
alone in patients with stage 2 hypertension. 
The extent to which the combination of a renin inhibitor with an angiotensin
receptor blocker (ARB) lowers clinic and ambulatory blood pressure (BP) versus an
ARB alone in stage 2 hypertension is not well known. Hence, we performed an
8-week, randomized, double-blind study in 451 patients with stage 2 hypertension
to compare the efficacy of the combination of aliskiren/valsartan 300/320 mg
versus valsartan 320 mg...
Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. [2008.12]
INTRODUCTION: Patients with stage 2 hypertension require large absolute reductions in blood pressure (BP) to achieve recommended BP goals. Combination therapy with the direct renin inhibitor, aliskiren, and the angiotensin receptor blocker, valsartan, has been shown to produce greater BP reductions than either agent alone in a double-blind study in 1797 hypertensive patients... CONCLUSION: Combination therapy with aliskiren and valsartan provided significantly greater BP reductions over aliskiren or valsartan monotherapy and is an appropriate option for management of BP in patients with stage 2 hypertension.
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. [2007.07.21]
BACKGROUND: The aim of this study was to assess dual renin system intervention with the maximum recommended doses of aliskiren and valsartan, compared with each drug alone in patients with hypertension... INTERPRETATION: The combination of aliskiren and valsartan at maximum recommended doses provides significantly greater reductions in blood pressure than does monotherapy with either agent in patients with hypertension, with a tolerability profile similar to that with aliskiren and valsartan alone.
Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and
nondipper hypertensive patients: a pooled analysis. 
This pooled analysis of ambulatory blood pressure (BP) monitoring data from two
8-week randomized controlled trials compared the antihypertensive efficacy and
safety of combination aliskiren/valsartan vs valsartan alone in hypertensive
patients (nocturnal dippers or nondippers)...
Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. [2011.07]
Combinations of the direct renin inhibitor aliskiren with angiotensin receptor blockers (ARBs) or diuretics are effective therapeutic regimens for the treatment of hypertension. A large database of safety information has become available during the past several years with aliskiren in combination trials...
Clinical Trials Related to Valturna (Aliskiren / Valsartan)
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes [Recruiting]
This is a study to assess the safety and efficacy of Valturna and amlodipine or Valturna and
chlorthalidone when compared to Valturna alone in patients with stage 2 hypertension and
diabetes mellitus 2.
The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome [Recruiting]
Study purpose: African Americans with hypertension and markers of metabolic syndrome (small
elevations in blood glucose, triglycerides and or weight) are at a high risk of
cardiovascular (heart and blood vessel) problems. There is a circulating factor called
angiotensin II that increases risk and may be more important in African Americans who have
up to 20 times greater risk of losing kidney function and requiring dialysis. Research
Investigators, including those at the University of Michigan, found one drug (Ramipril) that
blocks angiotensin II effects significantly and improves kidney function in African
The purpose of The SAAVE Study is to determine whether the combination of two new blockers
(Valsartan and Aliskiren) of angiotensin II, are better able to lower blood pressure, also
improve some of the risk factors for cardiovascular problems and provide greater protection
to the heart and kidneys.
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus [Recruiting]
The purpose of the study is to evaluate the blood pressure (BP)-lowering efficacy of the
combination of aliskiren and valsartan, as initial therapy, compared to valsartan
monotherapy in Type II Diabetic patients with Stage II hypertension.
Aliskiren on Retinal Vasculature Treatment Study [Recruiting]
Hypertension affects approximately one fourth of the world population and therefore
contributes substantially to the worldwide burden of cardiovascular (CV) disease and
Changes in small artery structure characterized by an increased wall-to-lumen ratio (WLR)
are characteristic feature of target organ damage in hypertension. Of clinical importance,
structural arteries of small subcutaneous arteries have been shown to be of prognostic
significance, with adverse prognosis in subjects with higher WLR. However, the assessment of
arteriolar structure from biopsies of subcutaneous tissue is invasive and impractical in
clinical practice. A new approach focuses on retinal arteriolar structural parameters by
using scanning laser Doppler flowmetry (SLDF) with automatic full-field perfusion imaging
analyses (9). This approach allows the non-invasive assessment of both the outer diameter
(OD) and inner diameter (ID) of retinal arterioles in vivo and, thus, analyses vascular
remodeling of retinal arterioles by calculating WLR = (OD - ID) / ID).
A crucial role in the efforts of prevention of end-organ damage plays the renin angiotensin
system (RAS). The increased mechanical strain on the vasculature at a higher BP can cause
injury to the endothelial wall. Activation of the RAS increases BP and stimulates a local
inflammatory response to repair the injury. Long-term or repeated response to injury leads
to endothelial dysfunction and microvascular damage, and hence end-organ damage.
Combining RAS inhibitors may provide greater end-organ protection than use of either class
alone. However, ONTARGET has failed to show superiority of the dual RAS blockade (ACE-I and
ARB) in patients at high cardiovascular risk. The combination of ARBs and direct renin
inhibitors (DRIs) emerged as the only available, valid and innovative option for blocking
the RAS at two different sites (sequential blockade). Indeed, AVOID study and ALLAY study
demonstrated that the DRI aliskiren has additional and to some extent blood pressure
independent effects on albuminuria and left ventricular hypertrophy, both signs of
subclinical organ damage in hypertension, respectively.
However, no data are available with respect to the effects of ARBs and DRIs on vascular
properties in the short and long term To close this gab we focus in this study on vascular
structural and functional changes since vascular adaptation to high blood pressure occurs in
the early phase of hypertensive disease.
Reports of Suspected Valturna (Aliskiren / Valsartan) Side Effects
Cerebrovascular Accident (22),
Blood Pressure Increased (16),
Diabetes Mellitus (15),
Renal Disorder (15),
Drug Ineffective (10),
Blood Pressure Fluctuation (10),
Road Traffic Accident (8), more >>